While we know there are certain clinical features serving as predictors that patients with SSc may develop ILD, including diffuse skin disease and serologies such as anti-Scl-70 and Th/To antibodies, it is imperative that clinicians consider that any patient, particularly early in their disease course (5 years of disease since the first non-Raynaud phenomenon symptom) could develop ILD.
🎓 Learning just got smarter. Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates. ?
Tweet Content
🎓 Learning just got smarter.
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
💡 Educational
🎯 Evidence-based
🧠 Addictive (in a good way)
Try it now and level up your clinical knowledge: https://t.co/JWTPUViFkI https://t.co/DsKunA4DkQ
Links
RheumIQ Weekly Quiz | RheumNow
https://buff.ly/KI7jFdp
